A High-Grade Glioma, Not Elsewhere Classified in an Older Adult with Discordant Genetic and Epigenetic Analyses

Author:

Yuen Carlen A.1ORCID,Bao Silin2,Kong Xiao-Tang1ORCID,Terry Merryl3,Himstead Alexander4,Zheng Michelle5,Pekmezci Melike3ORCID

Affiliation:

1. Neuro-Oncology Division, Department of Neurology, University of California, Irvine, CA 92868, USA

2. Neurosciences Division, Department of Internal Medicine, Community Regional Medical Center, Fresno, CA 93721, USA

3. Department of Pathology, University of California, San Francisco, CA 94143, USA

4. Department of Neurosurgery, University of California, Irvine, CA 92868, USA

5. UC Irvine Charlie Dunlop School of Biological Sciences, University of California, Irvine, CA 92697, USA

Abstract

The World Health Organization’s (WHO) classification of central nervous system (CNS) tumors is continually being refined to improve the existing diagnostic criteria for high-grade gliomas (HGGs), including glioblastoma. In 2021, advances in molecular analyses and DNA methylation profiling were incorporated to expand upon the diagnostic criteria for HGG, including the introduction of high-grade astrocytoma with piloid features (HGAP), a new tumor entity for which a match to the HGAP class in DNA methylation profiling is an essential criterion. We present an equivocal case of a 72-year-old male with an HGG exhibiting features of both HGAP and glioblastoma, but which did not conform to any existing 2021 WHO classification of CNS tumor entities. This “no match” in DNA methylation profiling resulted in a final diagnosis of HGG not elsewhere classified (NEC), for which standard treatment options do not exist.

Publisher

MDPI AG

Reference37 articles.

1. DNA methylation-based classification of central nervous system tumours;Capper;Nature,2018

2. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: The Heidelberg experience;Capper;Acta Neuropathol.,2018

3. Methylation array profiling of adult brain tumours: Diagnostic outcomes in a large, single centre;Jaunmuktane;Acta Neuropathol. Commun.,2019

4. WHO 2021 and beyond: New types, molecular markers and tools for brain tumor classification;Tran;Curr. Opin. Oncol.,2022

5. DNA methylation and its basic function;Moore;Neuropsychopharmacology,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3